La Baixa morbiditat perioperatòria de la prostatectomia radical laparoscòpica justifica efectuar-la en pacients majors de 70 anys

Donat l’increment en l’esperança de vida, valorem el tractament radical del càncer de pròstata en pacients & 70 anys. L’objectiu és analitzar la incidència, severitat i maneig de la morbiditat perioperatòria de la prostatectomia radical (PR) en funció de la tècnica quirúrgica. De 500 PR revisem, retrospectivament, 70 pacients & 70 anys (40 Retropúbiques i 30 Laparoscòpiques). S’empra la classificació de Clavien modificada per analitzar les complicacions. La proporció de complicacions és en PRR 57,5% i en PRL 33%. Les complicacions en la PRL són de menor gravetat. Els beneficis atribuïts a la laparoscòpia es mantenen en pacients d’edat avançada.

Fenilefrina intracamerular en el síndrome del iris flácido intraoperatorio

La incidència d’hipertròfia benigna de pròstata és aproximadament d’un 50 % en pacients majors de 50 anys. La Tamsulosina és el medicament més prescrit per aquesta dolència i la principal causa del síndrome d’iris flàccid intraoperatori a la cirurgia de cataractes. Els nostres dos estudis han sigut; per una banda, avaluar la toxicitat corneal i afectació cardíaca de Fenilefrina intracamerular a una concentració de 2,5% respecte la pauta de dilatació tòpica estàndard al nostre centre, i per l’altra, comparar l’ efectivitat i diferència al recompte endotelial de Fenilefrina intracamerular a una concentració de 2,5% respecte a una altra concentració del 1,66 %, mesurant els seus efectes en diverses variables.

Valoración del estudio vesical y del tracto urinario superior en pacientes con citología urinaria positiva y pruebas de imagen negativas

Introducció: La citologia urinària positiva en context de cistoscopia sense evidència de tumor macroscòpic obliga a continuar el seu estudi. En el nostre centre es realitzen biòpsies vesicals múltiples normatitzades (BMN) i citologia ureteral selectiva en aquest casos. Material i mètodes: Estudi retrospectiu de 70 pacients amb citologia urinària positiva en absència de tumor macroscòpic. Es van avaluar els resultats de totes les biòpsies vesicals múltiples i les citologies ureterals selectives realitzades. Resultats: Es va diagnosticar CIS vesical em 45 (64,3%) pacients. Es va detectar citologia ureteral positiva em 12: cinc (7,2%) en el costat esquerre i set (10%) en el dret. Es va observar CIS vesical concomitant em 2 de 5 pacients amb PAP ureteral positiu esquerra i em 5 de 7 amb PAP ureteral positiu dret. Conclusions: La biòpsia múltiple normatitzada (BMN) és útil per a aquest casos. Els pobres resultats obtinguts en citologia ureteral selectiva posen en dubte la rendibilitat de la seva utilització sistemàtica.

Tumores parotídeos: revisión de la distribución demográfica y de la correlación cito-histológica de los pacientes intervenidos por el servicio de Cirugía Maxilofacial del Hospital Universitario Vall d’Hebron

Els tumors parotidis constitueixen un motiu de consulta freqüent en el medi hospitalari. Per conèixer l’origen cel•lular dels mateixos disposem de l’anàlisi citològic pre-quirúrgic. No existeix una correlació exacta entre la citologia pre-quirúrgica i l’anatomia patològica definitiva segons la literatura. S’ha realitzat un estudi retrospectiu de sèries de casos dels pacients atesos per tumors parotidis al servei de Cirurgia Maxil•lofacial de l’Hospital Vall d’Hebron en el qual s’ha avaluat la distribució demogràfica d’aquests tumors i la correlació cito-histològica comparant-la amb altres sèries.

Proteinuria de rango nefrótico y nefroangiosclerosis. Características clínicas y evolutivas diferenciales.

La proteïnúria de rang nefròtic (&3g/24h) sol considerar-se secundària a una malaltia glomerular. Coincidint amb altres autors hem observat que alguns pacients amb biòpsies renals indicades per proteïnúria de rang nefròtic han estat diagnosticats de nefroangiosclerosi hipertensiva (NAS-HTA). Presentem un estudi retrospectiu en el qual descrivim les característiques clíniques i evolutives d’aquests pacients en comparació amb pacients amb proteïnúria de rang nefròtic d’altres etiologies. Concluïm que s’hauria d’incloure la NAS-HTA en el diagnòstic diferencial de la proteïnúria de rang nefròtic. L’absència d’edemes i una albúmina normal serien un indicador clínic diferenciador amb altres patologies que cursen amb proteïnuria de rang nefròtic i podrien servir d’ajuda en la presa de decisions quan la realització d’una biòpsia renal és controvertida.

Granulomatosis de Wegener: estudio de 15 casos, supervivencia y daño crónico

La granulomatosi de Wegener i la síndrome de Churg-Strauss són vasculitis granulomatoses de petit i mitjà vas. Es diagnostiquen mitjançant clínica i biòpsia compatible, i s'associen amb anticossos anticitoplasma de neutròfils. S'ha realitzat un estudi retrospectiu (1984 - 2010) a l'Hospital Universitari Germans Trias i Pujol. Es presenten 15 pacients amb granulomatosi de Wegener. Les característiques clíniques de la present sèrie no difereixen de les descrites prèviament. Es va comparar la supervivència i el dany crònic acumulat en els pacients amb aquestes dues vasculitis. Tant la mortalitat com el dany crònic acumulat resultà superior en el grup de malalts amb granulomatosi de Wegener.

Protocolo diagnóstico y seguimiento de la prevalencia e incidencia del virus del papiloma humano (vph) y las anormalidades citológicas de la mucosa anal de hombres que tienen sexo con hombres (hsh) e infección por el virus de la inmunodeficiencia humana (vih).

La citologia anal és un mètode sensible en el despistatge de la neoplàsia de canal anal i similar a la biòpsia dirigida mitjançant rectoscopi i tinció amb àcid acètic al 5%, sobretot en lesions d’alt grau de malignitat; a més de ser una prova adequada en el seguiment d’aquestes lesions. Els pacients VIH homes que tenen sexe amb altres homes tenen major incidència i prevalència de virus papiloma humà i major nombre d’anormalitats en la mucosa del canal anal que els VIH negatius.

Fascitis eosinofílica. A propósito de 13 casos.

Es tracta de la descripció d'una sèrie de 13 pacients amb fascitis eosinofílica diagnosticats en un hospital universitari entre 1989 i 2009. És una síndrome esclerodermiforme que es caracteritza per induració cutània i engruiximent i inflamació de la fàscia profunda. Es descriuen les característiques clíniques, el tractament rebut i l'evolució de 9 homes i 4 dones, amb una edat mitjana de 50 anys. Es va realitzar biòpsia profunda en tots els casos i els canvis van ser compatibles amb fascitis eosinofílica. Les característiques descrites en aquesta sèrie no difereixen de les descrites per altres autors.

Mejora diagnóstica de hepatopatías de afectación difusa mediante técnicas de inteligencia artificial

The automatic diagnostic discrimination is an application of artificial intelligence techniques that can solve clinical cases based on imaging. Diffuse liver diseases are diseases of wide prominence in the population and insidious course, yet early in its progression. Early and effective diagnosis is necessary because many of these diseases progress to cirrhosis and liver cancer. The usual technique of choice for accurate diagnosis is liver biopsy, an invasive and not without incompatibilities one. It is proposed in this project an alternative non-invasive and free of contraindications method based on liver ultrasonography. The images are digitized and then analyzed using statistical techniques and analysis of texture. The results are validated from the pathology report. Finally, we apply artificial intelligence techniques as Fuzzy k-Means or Support Vector Machines and compare its significance to the analysis Statistics and the report of the clinician. The results show that this technique is significantly valid and a promising alternative as a noninvasive diagnostic chronic liver disease from diffuse involvement. Artificial Intelligence classifying techniques significantly improve the diagnosing discrimination compared to other statistics.

Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)

The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR and p53 pathways. We investigated the genetic variability of 67 key genes in the mTOR pathway and in genes of the p53 pathway which interact with mTOR. We tested the association of 1,084 tagging SNPs with prostate cancer risk in a study of 815 prostate cancer cases and 1,266 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). We chose the SNPs (n = 11) with the strongest association with risk (p<0.01) and sought to replicate their association in an additional series of 838 prostate cancer cases and 943 controls from EPIC. In the joint analysis of first and second phase two SNPs of the PRKCI gene showed an association with risk of prostate cancer (ORallele = 0.85, 95% CI 0.78–0.94, p = 1.3×10−3 for rs546950 and ORallele = 0.84, 95% CI 0.76–0.93, p = 5.6×10−4 for rs4955720). We confirmed this in a meta-analysis using as replication set the data from the second phase of our study jointly with the first phase of the Cancer Genetic Markers of Susceptibility (CGEMS) project. In conclusion, we found an association with prostate cancer risk for two SNPs belonging to PRKCI, a gene which is frequently overexpressed in various neoplasms, including prostate cancer.

Is hospital discharge administrative data an appropriate source of information for cancer registries purposes? Some insights from four Spanish registries

Background. The use of hospital discharge administrative data (HDAD) has been recommended for automating, improving, even substituting, population-based cancer registries. The frequency of false positive and false negative cases recommends local validation. Methods. The aim of this study was to detect newly diagnosed, false positive and false negative cases of cancer from hospital discharge claims, using four Spanish population-based cancer registries as the gold standard. Prostate cancer was used as a case study. Results. A total of 2286 incident cases of prostate cancer registered in 2000 were used for validation. In the most sensitive algorithm (that using five diagnostic codes), estimates for Sensitivity ranged from 14.5% (CI95% 10.3-19.6) to 45.7% (CI95% 41.4-50.1). In the most predictive algorithm (that using five diagnostic and five surgical codes) Positive Predictive Value estimates ranged from 55.9% (CI95% 42.4-68.8) to 74.3% (CI95% 67.0-80.6). The most frequent reason for false positive cases was the number of prevalent cases inadequately considered as newly diagnosed cancers, ranging from 61.1% to 82.3% of false positive cases. The most frequent reason for false negative cases was related to the number of cases not attended in hospital settings. In this case, figures ranged from 34.4% to 69.7% of false negative cases, in the most predictive algorithm. Conclusions. HDAD might be a helpful tool for cancer registries to reach their goals. The findings suggest that, for automating cancer registries, algorithms combining diagnoses and procedures are the best option. However, for cancer surveillance purposes, in those cancers like prostate cancer in which care is not only hospital-based, combining inpatient and outpatient information will be required.

A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

Background: Androgens are key regulators of prostate gland maintenance and prostate cancer growth, and androgen deprivation therapy has been the mainstay of treatment for advanced prostate cancer for many years. A long-standing hypothesis has been that inherited variation in the androgen receptor (AR) gene plays a role in prostate cancer initiation. However, studies to date have been inconclusive and often suffered from small sample sizes. Objective and Methods: We investigated the association of AR sequence variants with circulating sex hormone levels and prostate cancer risk in 6058 prostate cancer cases and 6725 controls of Caucasian origin within the Breast and Prostate Cancer Cohort Consortium. We genotyped a highly polymorphic CAG microsatellite in exon 1 and six haplotype tagging single nucleotide polymorphisms and tested each genetic variant for association with prostate cancer risk and with sex steroid levels. Results: We observed no association between AR genetic variants and prostate cancer risk. However, there was a strong association between longer CAG repeats and higher levels of testosterone (P = 4.73 × 10−5) and estradiol (P = 0.0002), although the amount of variance explained was small (0.4 and 0.7%, respectively). Conclusions: This study is the largest to date investigating AR sequence variants, sex steroid levels, and prostate cancer risk. Although we observed no association between AR sequence variants and prostate cancer risk, our results support earlier findings of a relation between the number of CAG repeats and circulating levels of testosterone and estradiol.

Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis

Objectives: A multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis. Materials and Methods: Males (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evaluated were: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence and time-to-appearance. Medication tolerance and treatment satisfaction were assessed using a questionnaire. Results: A total of 170 that matched all the inclusion criteria (78%) out of 218 were evaluable for efficacy. There was a measurable statistically significant reduction in pain at rest and on movement as well as an improvement in the quality of life compared with baseline. Best results were obtained with early treatment. Overall incidence of bone events was 11.2%. Of the 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed satisfaction with the treatment Discussion: Zoledronic acid is effective for reducing pain, improving mobility, and increasing the quality of life in patients with prostate cancer with bone metastasis. Its easy administration and good tolerability make zoledronic acid one of the principal therapeutic tools in the management of patients with pain associated with bone metastasis from prostate cancer.

Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer

BACKGROUND Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. The purpose of this study was to investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-inflammatory cytokines and chemokines are associated with an increased prostate cancer risk. METHODS A case-control study design was used to test the association between prostate cancer risk and the polymorphisms TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-889 C/T (rs 1800587) and MCP-1 2518 G/A (rs 1024611) in 296 patients diagnosed with prostate cancer and in 311 healthy controls from the same area. RESULTS Diagnosis of prostate cancer was significantly associated with TNF-A GA + AA genotype (OR, 1.61; 95% CI, 1.09-2.64) and RANTES GA + AA genotype (OR, 1.44; 95% CI, 1.09-2.38). A alleles in TNF-A and RANTES influenced prostate cancer susceptibility and acted independently of each other in these subjects. No epistatic effect was found for the combination of different polymorphisms studied. Finally, no overall association was found between prostate cancer risk and IL1-A or MCP-1 polymorphisms. CONCLUSION Our results and previously published findings on genes associated with innate immunity support the hypothesis that polymorphisms in proinflammatory genes may be important in prostate cancer development.

Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.

Androgen-sensitive prostate cancer cells turn androgen resistant through complex mechanisms that involve dysregulation of apoptosis. We investigated the role of antiapoptotic Bcl-xL in the progression of prostate cancer as well as the interactions of Bcl-xL with proapoptotic Bax and Bak in androgen-dependent and -independent prostate cancer cells. Immunohistochemical analysis was used to study the expression of Bcl-xL in a series of 139 prostate carcinomas and its association with Gleason grade and time to hormone resistance. Expression of Bcl-xL was more abundant in prostate carcinomas of higher Gleason grades and significantly associated with the onset of hormone-refractory disease. In vivo interactions of Bcl-xL with Bax or Bak in untreated and camptothecin-treated LNCaP and PC3 cells were investigated by means of coimmunoprecipitation. In the absence of any stimuli, Bcl-xL interacts with Bax and Bak in androgen-independent PC3 cells but only with Bak in androgen-dependent LNCaP cells. Interactions of Bcl-xL with Bax and Bak were also evidenced in lysates from high-grade prostate cancer tissues. In LNCaP cells treated with camptothecin, an inhibitor of topoisomerase I, the interaction between Bcl-xL and Bak was absent after 36 h, Bcl-xL decreased gradually and Bak increased coincidentally with the progress of apoptosis. These results support a model in which Bcl-xL would exert an inhibitory effect over Bak via heterodimerization. We propose that these interactions may provide mechanisms for suppressing the activity of proapoptotic Bax and Bak in prostate cancer cells and that Bcl-xL expression contributes to androgen resistance and progression of prostate cancer.